EPO and anemia (phenotype): In other words, low-dose roxadustat combined with erythropoietin therapy not only improves anemia and relieves ESA resistance but also reduces the risk associated with adverse events of higher doses of roxadustat, which is worthy of clinical reference and application in ESA-hyporesponsive patients.